Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands

Harm Reduction Journal

Volumn 7, Issue , 2010, Pages

  Schreuder, Imke ^a,b   van der Sande, Marianne A B ^b,f   de Wit, Matty ^c   Bongaerts, Monique ^d   Boucher, Charles A B ^a   Croes, Esther A ^e   van Veen, Maaike G ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^d Division Addiction Care Group   (Netherlands)

^e NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; COCAINE; HEPATITIS B VACCINE; METHADONE; OPIATE;

ADULT; ARTICLE; CLINICAL STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METHADONE TREATMENT; NETHERLANDS; OPIATE ADDICTION; SCREENING; SEROPREVALENCE; VACCINATION;

EID: 77958120293     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-7-25     Document Type: Article

References (40)

1. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of Drug Preparation Equipment as a Risk Factor for Hepatitis C. American Journal of Public Health 2001, 91:1.
2. Mathei C, Buntinx F, Damme van P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. Journal of Viral Hepatitis 2002, 9(3):157-173. 10.1046/j.1365-2893.2002.00339.x, 12010503.
3. Murrill CS, Weeks H, Castrucci BC, Weinstock HS, Bell BP, Spruill C, Gwinn M. Age-Specific Seroprevalence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infection Among Injection Drug Users Admitted to Drug Treatment in 6 US Cities. American Journal of Public Health 2002, 92(3):385-387. 10.2105/AJPH.92.3.385, 1447085, 11867316.
4. Merkinaite S. HCV infection in Europe. World Hepatitis Awareness Day (WHAD): October 1st 2007; Brussels 2007, Eurasian Harm Reduction Network.
5. European Monitoring Centre for Drugs and Drug Addiction HIV among IDUs in Europe: increasing trends in the East. 2009, EMCDDA, Lisbon, European Monitoring Centre for Drugs and Drug Addiction.
6. Rodenburg G, Spijkerman R, Eijnden van den R, Mheen van de D. Nationaal prevalentieonderzoek middelengebruik 2005. Instituut voor Onderzoek naar Leefwijzen & Verslaving. 2007, IVO, Rotterdam.
7. Driessen F, Noorlander E. Handboek verslaving 2004, Houten/Diegen: Bohn Stafleu van Loghum, [in Dutch].
8. Netherlands Institute for Mental Health and Addiction National drug monitor, annual report 2009 2010, Trimbos Institute, Utrecht, Netherlands Institute for Mental Health and Addiction.
9. Trimbosinstituut factsheet Infectieziekten en druggebruik in Nederland. 2007, Netherlands institute for mental health and addiction (Trimbosinstitute), [in Dutch], Trimbosinstituut factsheet.
10. van Ameijden EJ, Coutinho RA. Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions. J Epidemiol Community Health 2001, 55(5):356-63. 10.1136/jech.55.5.356, 1731889, 11297661.
11. Marlatt AG. Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors 2002, Ney York: Guilford Press.
12. van den Berg C, Smit C, van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programs is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007, 102(9):1454-1462. 10.1111/j.1360-0443.2007.01912.x, 2040242, 17697278.
13. Drugs policy in the Netherlands. , http://www.healthlaw.nl/drugs1.html
14. Buster MCA, Brussel van GHA, Brink van den W. Estimating the number of opiate users in Amsterdam by capture recapture; the importance of case definition. European journal of epidemiology 2001, 17:935-42. 10.1023/A:1016256929862, 12188014.
15. Loth CA, Oliemeulen EAP, Jong de CAJ. Richtlijn opiaat Onderhoudsbehandeling (RIOB). 2005, Amersfoort, [in Dutch].
16. Koedijk F, Vriend HJ, van Veen MG, Op de Coul ELM, van den Broek IVF, van Sighem AI, Verheij RA, van der Sande MAB. Sexually Transmitted Infections, including HIV, in the Netherlands in 2008. RIVM annual report 210261005/2009 2009, Bilthoven.
17. National coordination for infectious diseases control LCI protocol Hepatitis C 2005, RIVM, Bilthoven, [in Dutch], National coordination for infectious diseases control.
18. Beuker RJ, Berns MPH, van Rozendaal CM, Snijders BM, van Ameijden EJC, Houweling H, van de Laar MJW. Surveillance van HIV-infectie onder injecterende druggebruikers in Nederland: meting Amsterdam 1998. RIVM rapport 441100011 1999, Bilthoven, [in Dutch].
19. Beuker RJ, Berns MPH, van Rozendaal CM, Snijders BM, Jansen M, Hoebe CJPA, van de Laar MJW. Surveillance van HIV-infectie onder injecterende druggebruikers in Nederland: meting Heerlen/Maastricht 1998/1999. RIVM rapport 441100014 2001, Bilthoven, [in Dutch].
20. Beuker RJ, Berns MPH, Watzeels JCM, Hendriks VM, de Coster EJM, van der Marel TE, van de Laar MJW. Surveillance van HIV-infectie onder injecterende druggebruikers in Nederland: meting Den Haag 2000. RIVM rapport 441100015 2001, Bilthoven, [in Dutch].
21. Carsauw HHC, van Rozendaa CM, Scheepens JMFA, Hoebe CJPA, Meulders WAJ, Jansen M, Dorigo-Zetsma JW, Houweling H. Infecties met HIV, HBV en HCV onder injecterende druggebruikers in Heerlen/Maastricht. RIVM rapport 441100006 1997, Bilthoven, [in Dutch].
22. de Boer IM, Op de Coul ELM, Beuker RJ, de Zwart O, Al Taqatqa W, van de Laar MJW. Trends in HIV-prevalentie en risicogedrag onder injecterende druggebruikers in Rotterdam, 1994-2002. Ned Tijdschr Geneeskd 2004, 148(47). [in Dutch].
23. van Houdt R, Koedijk FHD, Bruisten SM, Op de Coul ELM, Heijnen MLA, Waldhober OO, Veldhuijzen IK, Richardus JH, Schutten M, van Doornum GJJ. Hepatitis B vaccination targeted at behavioural risk groups in the Netherlands: Does it work?. Vaccine 2009, 27:3530-3535. 10.1016/j.vaccine.2009.03.072, 19464531.
24. Lelij van der B, Driessen FMHM. Een onderzoek van aanbod en gebruik bij instellingen die deelnemen aan het heroïneverstrekkingsexperiment 1998, Bureau Driessen, Sociaal Wetenschappelijk Onderzoek: Utrecht, [in Dutch]., http://www.bureaudriessen.nl/publicaties/slot-her.html
25. Serpelloni G, Carrieri MP, Rezza G, Morganti S, Gomma M, Binkin N. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study. AIDS Care 1994, 6(2):215-20. 10.1080/09540129408258632, 8061081.
26. Gibsona DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999, 13:1807-1818. 10.1097/00002030-199910010-00002, 10513638.
27. European Monitoring Centre for Drugs and Drug Addiction Annual report: the state of the drug problem in Europe. 2009, EMCDDA, Lisbon, European Monitoring Centre for Drugs and Drug Addiction.
28. Wiessing L, Laar van de MJ, Donoghoe MC, Guarita B, Klempova D, Griffiths P. HIV among injecting drug users in Europe: increasing trends in the East. Eurosurveillance, rapid communications 2008, 13(50).
29. Strauss SM, Astone JM, Hagan H, Des Jarlais DC. The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units. J Urban Health 2004, 81(1):38-47.
30. Lamden KH, Kennedy N, Beeching NJ, Lowe D, Morrison CL, Mallinson H, Mutton KJ, Syed Q. Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. Journal of Infection 1998, 37:260-269. 10.1016/S0163-4453(98)92045-X, 9892530.
31. Quaglio GL, Lugoboni F, Pajusco B, Sarti M, Talamini G, Lechi A, Mezzelani P, Des Jarlais DC. Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis 2003, 37:33-40. 10.1086/375566, 12830406.
32. van Dam M. National Institute for the Environment and Health, department of Personal communication. 2009,
33. Carter H, Robinson G, Hanlon C, Hailwood C, Massarotto A. Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. N Z Med J 2001, 114(1136):324-6.
34. McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis 2001, 20(1):19-31. 10.1300/J069v20n01_03, 11286428.
35. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005, 40(Suppl 5):S339-45. 10.1086/427450, 15768345.
36. Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 2008, 103(6):905-18. 10.1111/j.1360-0443.2008.02188.x, 18422827.
37. Taylor LE. Delivering Care to Injection Drug Users Coinfected with HIV and Hepatitis C Virus. Clinical Infectious Diseases 2005, 40:S355-61. 10.1086/427453, 15768348.
38. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008, 33(3):126-33. 10.1007/s10900-007-9083-3, 18165889.
39. Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F. Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of Hep 2005, 42(3):323-328.
40. National coordination for infectious diseases control LCI protocol Hepatitis B 2008, RIVM, Bilthoven, [in Dutch], National coordination for infectious diseases control.